|Bid||10.81 x 800|
|Ask||11.99 x 1800|
|Day's Range||11.00 - 11.41|
|52 Week Range||6.81 - 17.39|
|Beta (5Y Monthly)||0.37|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]
Biotech investment is fraught with risk. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts. These binary events , however, provide an opportunity for making ...
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see...
AMAG Pharmaceuticals (AMAG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Investors need to pay close attention to AMAG Pharmaceuticals (AMAG) stock based on the movements in the options market lately.
The number of pharmaceutical and biotechnology companies seeking Chapter 11 protection has nearly tripled the 10-year average in 2019 and is expected to continue to rise Continue reading...
Hedge funds and other investment firms that we track manage billions of dollars of their wealthy clients' money, and needless to say, they are painstakingly thorough when analyzing where to invest this money, as their own wealth also depends on it. Regardless of the various methods used by elite investors like David Tepper and David […]
AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of -37.25% and -5.78%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Shares of Amag Pharmaceuticals collapsed Wednesday after a split Food and Drug Administration advisory committee voted 9-7 to pull its preterm birth prevention drug, Makena, from the market.
AMAG said the FDA's Bone and Reproductive and Urologic Advisory Committee, which met to discuss the PROLONG confirmatory trial for its Makena, voted 9-7 in favor of pulling the product out of the market. Makena is hydroxyprogesterone caproate injection approved in 2011 to reduce preterm birth in pregnant women who have had a prior spontaneous preterm birth.
In a surprising move, an FDA advisory committee has recommended that the agency pull Amag Pharmaceuticals' cornerstone product and only approved drug designed to stop pre-term birth off of the market.
Shares of biotech company Amag Pharmaceuticals jumped Monday ahead of a Food and Drug Administration panel to discuss its drug, Makena. Makena is used to prevent premature birth.
Attorney and proxy fight expert Kai Liekefett estimated that upwards of 10 percent of public companies have faced activist investor challenges so far this year.
Earnings, clinical trial readouts and positive FDA verdicts catalyzed fairly robust performances by biotech stocks last week. Biogen Inc (NASDAQ: BIIB )'s about-face with respect to its Alzheimer's drug ...
AMAG Pharmaceuticals (AMAG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amag Pharmaceuticals Inc, whose shares have tumbled more than 45% in the past year, on Tuesday agreed to add two directors proposed by Caligan Partners after the hedge fund pressured the drugmaker to conduct a strategic business review. Amag, which won U.S. approval for a female libido drug in June, said it will expand its board to 11 people, making room for Caligan Partners' founder David Johnson and Paul Fonteyne, a former head of Boehringer Ingelheim USA. The hedge fund, which owns a 10.3% stake in Amag, had for months been pressing for changes ranging from cost cuts to possibly splitting up the company or finding partnerships, and had proposed adding four new directors to the board.
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...